Comunicados de prensa de Vertex Pharmaceuticals

BOSTON --(BUSINESS WIRE)--Oct. 20, 2026-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Daniel Brennan has been appointed to its Board of Directors as an independent director…

- Data on ALYFTREK in children ages 2 to 5 years demonstrate recovery of pancreatic function in some children – - Additional abstracts on clinical and real-world evidence on CFTR modulators also prese…

BOSTON --(BUSINESS WIRE)--Oct. 7, 2026-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its third quarter 2026 financial results on Monday, November 2, 2026, after the financial market…

– In people with AMKD with modest proteinuria, treatment with inaxaplin led to a reduction in urine albumin to creatinine ratio (UACR) of -42.7% at Week 13 compared to baseline – - In people with AMKD…

- Vonn shares her experience using JOURNAVX to manage her acute pain after a career-altering injury at the 2026 Winter Games - BOSTON --(BUSINESS WIRE)--Sep. 15, 2026-- Vertex Pharmaceuticals Incorpor…

Vertex Pharmaceuticals (Germany) GmbH: München (ots) - - Der "Sickle Cell Awareness Month" im September rückt die Sichelzellkrankheit stärker ins öffentliche Bewusstsein und unterstreicht die Bedeutun…

Crinetics acquisition completed September 1, 2026 Charles Wagner, EVP, Chief Operating and Financial Officer to take on expanded COO role overseeing integration of Crinetics, effective immediately As…

BOSTON --(BUSINESS WIRE)--Aug. 26, 2026-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in four upcoming investor conferences. Susie Lisa, Senior Vice Pre…

— Total revenue of $3.33 billion, a 12% increase compared to second quarter 2025 — — Raising full-year revenue guidance to $13.1 billion to $13.2 billion — — Continued progress across research and dev…

BOSTON --(BUSINESS WIRE)--Jul. 7, 2026-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its second quarter 2026 financial results on Monday, August 3, 2026, after the financial markets…

- Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfolio - - PALSONIFY ®, Crinetics’ recently launched, fi…

- First and only approved genetic therapy to treat children as young as 2 years for both severe sickle cell disease and transfusion-dependent beta thalassemia - - Approximately 5,500 additional childr…

BOSTON --(BUSINESS WIRE)--Jun. 3, 2026-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in the Goldman Sachs 47th Annual Global Healthcare Conference. Dr.…

- FDA assigns Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2026 – BOSTON --(BUSINESS WIRE)--Jun. 1, 2026-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announc…

BOSTON --(BUSINESS WIRE)--May 11, 2026-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences. Charlie Wagner, Chief Operati…

-The agreement ensures sustainable access to this innovative therapy for eligible patients ages 12 years and older in Germany - BOSTON --(BUSINESS WIRE)--May 6, 2026-- Vertex Pharmaceuticals Incorpora…

BOSTON --(BUSINESS WIRE)--Apr. 6, 2026-- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2026 financial results on Monday, May 4, 2026, after the financial markets clo…